尿可溶性CD163有助于预测狼疮肾炎活动性并监测标准治疗反应
该单中心回顾性队列纳入214例系统性红斑狼疮患者,其中129例为狼疮肾炎并纵向评估。尿可溶性CD163/肌酐比值(usCD163/Cre)在区分活动性与非活动性狼疮肾炎、预测肾活检组织学活动性及鉴别疾病 flare 方面优于常规生物标志物,治疗3和6个月时的usCD163/Cre水平可独立预测完全、部分和无治疗反应。
要点
- usCD163/Cre区分活动性与非活动性狼疮肾炎的AUC为0.999,优于尿蛋白/肌酐比值(AUC=0.994)和血清白蛋白(AUC=0.940)。
- 肾活检时usCD163/Cre是组织学活动性的唯一可靠预测指标,AUC=0.962,阈值为1200 ng/mmol。
- 随访中usCD163/Cre鉴别疾病 flare 优于尿蛋白/肌酐比值,阈值为>520 ng/mmol。
核心结论
- 研究结果支持CD163阳性巨噬细胞(M2c)参与狼疮肾炎的病理生理过程,并主张将usCD163/Cre检测纳入狼疮肾炎标准管理,用于评估 flare 发作和作为治疗反应的早期预测指标。
研究设计与样本
- 单中心回顾性队列分析,纳入214例系统性红斑狼疮患者,其中129例为狼疮肾炎并纵向评估,39例在样本采集时接受了肾活检。
- 数据从医疗记录中提取,包括肾脏活动性指标(SLEDAI-R)、组织学特征和根据KDIGO 2024结局标准判定的治疗反应。
- 将usCD163/Cre(ELLA-G2)的特征与常规使用的生物标志物及混杂因素(包括肾功能和合并用药)进行比较。
主要发现
- 横断面分析显示,usCD163/Cre(AUC=0.999)、点尿蛋白/肌酐比值(AUC=0.994)和血清白蛋白水平(AUC=0.940)可区分活动性与非活动性狼疮肾炎,并与SLEDAI-R评分相关。
- 肾活检时,usCD163/Cre是组织学活动性的唯一可靠预测指标(AUC=0.962;阈值1200 ng/mmol)。
- 随访评估中,usCD163/Cre鉴别疾病 flare 优于尿蛋白/肌酐比值(阈值>520 ng/mmol)。
- 治疗开始后3和6个月时,将usCD163/Cre水平分为低(<520 ng/mmol)、中(520-1200 ng/mmol)和高(>1200 ng/mmol)三组,可作为独立因素预测完全、部分和无治疗反应者。
关键数值与推荐
- usCD163/Cre区分活动性与非活动性狼疮肾炎的AUC=0.999。
- 点尿蛋白/肌酐比值区分活动性与非活动性狼疮肾炎的AUC=0.994。
- 血清白蛋白区分活动性与非活动性狼疮肾炎的AUC=0.940。
- usCD163/Cre预测肾活检组织学活动性的AUC=0.962,阈值为1200 ng/mmol。
- usCD163/Cre鉴别疾病 flare 的阈值为>520 ng/mmol。
临床怎么用
- 作者主张将usCD163/Cre检测纳入狼疮肾炎标准管理,用于评估 flare 发作和作为治疗反应的早期预测指标。
- 治疗开始后3和6个月时,usCD163/Cre水平低于520 ng/mmol、520-1200 ng/mmol和高于1200 ng/mmol分别对应预测完全、部分和无治疗反应者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aims to assess urinary soluble CD163 normalized to creatinuria (usCD163/Cre) alongside conventional biomarkers as indicators of renal activity and therapeutic response in LN. METHODS: A monocentric and retrospective cohort analysis involving 214 patients with SLE was conducted, among whom 129 were referred as LN and assessed longitudinally. Of these, 39 underwent kidney biopsy at sample collection. Data were extracted from medical records, including metrics on renal activity (SLEDAI-R), histological characteristics and therapeutic response according to KDIGO 2024 outcome criteria. The characteristics of usCD163/Cre (ELLA-G2) were compared against routinely used biomarkers and confounding factors including renal function and concomitant medication use. RESULTS: The cross-sectional analysis indicated that usCD163/Cre [area under the curve (AUC) = 0.999], spot urine protein/creatinine ratio or PCR (AUC = 0.994) and serum albumin levels (AUC = 0.940) distinguished between active LN and inactive states, and correlated with SLEDAI-R scores. At the time of kidney biopsy, usCD163/Cre was the only reliable predictor of histological activity (AUC = 0.962; threshold 1200 ng/mmol). During follow-up assessments, usCD163/Cre outperformed PCR to discriminate disease flares (>520 ng/mmol), and categorization into low (<520 ng/mmol), medium (520-1200 ng/mmol) and high (>1200 ng/mmol) usCD163/Cre levels at 3 and 6 months, following therapy introduction, allows to predict complete, partial and non-responders as an independent factor. CONCLUSION: Our findings support the involvement of CD163 positive macrophages (M2c) in the pathophysiology of LN and advocate for the inclusion of usCD163/Cre measurement in the standard of LN management to assess LN flare episodes and as an early predictor of therapy response.
引用
- Renaudineau Y, Treiner E, Colombat M, et al. Urinary soluble CD163 is useful to predict lupus nephritis activity and to monitor standard-of-care therapy response. Rheumatology (Oxford). 2025. PMID: 40824081. doi:10.1093/rheumatology/keaf446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。